Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay

2005367 citationsJournal Article

Authors

H. Barton Grossman · The University of Texas MD Anderson Cancer Center

Abstract

The noninvasive point-of-care assay for elevated urinary NMP22 protein can increase the accuracy of cystoscopy, with test results available during the patient visit.

Topics & Keywords

Bladder and Urothelial Cancer Treatments Urinary and Genital Oncology Studies Esophageal Cancer Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 293, Issue 7, pp. 810-810

DOI: 10.1001/jama.293.7.810

Field-Weighted Citation Impact: 27.52